SEC Form 4 · accession 0001140361-17-025625
BIOMARIN PHARMACEUTICAL INC · BMRN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Henry J Fuchs
Officer — President, Worldwide R&D
Period of report
Jun 16, 2017
Accepted (ET)
Jun 20, 2017 · 6:33 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001048477
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jun 16, 2017 | M | 5,000 | $26.49 | A | 141,422 | D | |
| Common StockF1 | Jun 16, 2017 | M | 9,397 | $37.46 | A | 150,819 | D | |
| Common StockF1,F2 | Jun 16, 2017 | S | 5,000 | $90.00 | D | 145,819 | D | |
| Common StockF1,F2 | Jun 16, 2017 | S | 9,397 | $90.00 | D | 136,422 | D | |
| Common StockF1 | Jun 19, 2017 | M | 603 | $37.46 | A | 137,025 | D | |
| Common StockF1,F2 | Jun 19, 2017 | S | 603 | $90.00 | D | 136,422 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy) Common StockF1,F3 | $26.49 | Jun 16, 2017 | M | 5,000 | D | Nov 12, 2011 | May 11, 2021 | Common Stock | 5,000 | 15,225 | D |
| Stock Option (right to buy) Common StockF1,F3 | $37.46 | Jun 16, 2017 | M | 9,397 | D | Nov 8, 2012 | May 7, 2022 | Common Stock | 9,397 | 47,934 | D |
| Stock Option (right to buy) Common StockF1,F3 | $37.46 | Jun 19, 2017 | M | 603 | D | Nov 8, 2012 | May 7, 2022 | Common Stock | 603 | 47,331 | D |
Explanation of responses
- F1Trade made pursuant to a 10b5-1 plan executed on May 9, 2017.
- F2All shares sold at the same price.
- F3Reflects the number of options outstanding after the transactions from this specific stock option grant.